Protein

Description
Isoform 1 (1327 amino acids) contains region with homopolymeric runs of His, Pro, and Ser (HPS domain, aa 1-181), 15 ankyrin repeats (ANK 1 to 15, aa 215-934), multimerization domain homologous to the sterile alpha motif (SAM domain, aa 1030 (SAM domain, aa -1089 and PARP catalytic domain (aa 1112-1317). Isoform 2 (643 amino acids) contains only HPS domain and 9 ANK repeats.
Expression
Ubiquitous, high expression in brain and ganglions, skin and cardiac tissue.
Localisation
Nuclear and cytoplasmic.
Function
Poly(ADP-ribosyl)ation (PARsylation) of target proteins: TNKS itself, TNKS2/TNKL, TRF1, IRAP, TAB182/TNKS1BP1, EBNA-1, Mcl-1L, Mcl-1S, NuMA, AXIN1, AXIN2. TNKS PARsylates TRF1 (telomeric repeat-binding factor 1), a negative regulator of telomere length maintenance. PARsylated TRF1 dissociates from telomeres, enhancing telomerase-mediated telomere elongation (Smith and de Lange, 2000; Cook et al., 2002) . PARsylation of NuMA (nuclear mitotic apparatus protein) by TNKS contributes to mitotic spindle pole assembly (Sbodio and Chi, 2002) . TNKS can PARsylate Mcl-1L and Mcl-1S and inhibit their anti-and pro-apoptotic function correspondingly (Bae et al., 2003) . TNKS inhibits Epstein-Barr virus OriP function by binding and modifying Epstein-Barr nuclear antigen 1 (EBNA1) (Deng et al., 2002; Deng et al., 2005) . PARsylation activity of TNKS increases after phosphorilation by mitogen-activated protein kinase (MAPK) upon insulin stimulation (Chi and Lodish, 2000) . TNKS together with its partner IRAP enhances insulinstimulated exocytosis of GLUT4 (Yeh et al., 2007) . TNKS PARsylates AXIN1 and AXIN2 components of beta-catenin (the Wnt pathway transcription factor) destruction complex (Huang et al., 2009) . TNKS is a target of the FANCD2, the key protein involved in development of Fanconi anemia. FANCD binds tankyrase-1 and inhibits its PARsylation at telomeres (Lyakhovich et al., 2011) . 
Homology
With TNKS2/TNKL.
Mutations
Somatic
Frameshift mutations are found in exons 9 and 10 in gastric and colorectal malignant tumors (Kim et al., 2011) .
Implicated in
Cancer Note TNKS is considered as a potential target for anticancer treatment. Inhibition of PARP activities of TNKS blocks Wnt/beta-catenin pathway and increases efficiency of telomerase inhibitors (Seimiya et al., 2005; Huang et al., 2009; Zhang et al., 2010) . Disease TNKS expression increased in some tumors (compared to adjacent normal tissues), including breast, bladder and gastric cancer (Gelmini et al., 2004; Gelmini et al., 2007; Poonepalli et al., 2008; Gao et al., 2011) , but in other tumors, e.g. malignant glioma and colorectal cancer TNKS expression might be downregulated (Shervington et al., 2007; Shebzukhov et al., 2008) , Fanconi anemia (Lyakhovich et al., 2011) .
